SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing treatment for recurrent respiratory papillomatosis has put pressure on Precigens PAPZIMEOS and prompted debate over how much the new entrant could erode its market. Traders are weighing that competitive threat against Precigens first-mover position and full approval, while questioning whether Inovio can commercialize its accelerated-approval drug effectively.

Compound (COMP) is a cryptocurrency and operates on the Ethereum platform. Compound has a current supply of 10,000,000 with 9,999,999.99995246 in circulation. The last known price of Compound is 20.49527411 USD and is down -2.02 over the last 24 hours. It is currently trading on 652 active market(s) with $25,001,434.49 traded over the last 24 hours. More information can be found at https://www.compound.xyz/.

Compound

Compounds institutional-market pushincluding the market launch, a treasury-backed finance program and new leadershipis drawing attention, with bulls viewing it as a potential growth catalyst. Others remain skeptical, pointing to COMPs weak price action and questioning whether the initiative will translate into demand for the token.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM is drawing attention after raising its full-year outlook amid strong demand and elevated container freight rates, prompting traders to anticipate stronger earnings and dividends. Discussion is also divided over the uncertain Hapag-Lloyd takeover, with some favoring a deal while others see more value in ZIM remaining independent.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

Shares are under pressure as traders react to weak early sales of AstraZenecas competing hypertension drug, Baxfendy, raising concerns about the pace of uptake and lorundrostats commercial prospects as a later entrant. Some argue reimbursement and coverage take time to build, while others see the launch as evidence that sales potential may be slower or lower than expected.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,617.445403. The last known price of Zebec Network is 0.00204055 USD and is down -0.09 over the last 24 hours. It is currently trading on 133 active market(s) with $10,537,951.06 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Zebecs payments and payroll expansionespecially the MoneyGram-related news and reported Germany deploymentis drawing attention, with bulls viewing it as evidence of growing adoption. Skeptics argue that partnerships have yet to translate into stronger token performance or demonstrable demand, while some Robinhood and Ripple speculation remains unconfirmed.

Algorand (ALGO) is a cryptocurrency launched in 2019. Algorand has a current supply of 10,000,000,000 with 9,075,763,011.6159 in circulation. The last known price of Algorand is 0.09537939 USD and is up 2.17 over the last 24 hours. It is currently trading on 586 active market(s) with $72,099,657.31 traded over the last 24 hours. More information can be found at http://algorand.foundation.

Algorand

ALGO is drawing attention amid a price bounce and debate over whether technical support signals a broader recovery. Bulls cite new leadership and possible altcoin-season momentum, while skeptics point to the tokens prolonged decline and history of rallies fading.

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

A sharply stronger quarterly report and raised full-year outlook have fueled attention, alongside record energy volumes and managements discussion of advanced natural-gas deals for data centers and power generation. Many traders see growth potential and value in the rising distribution, while others are frustrated that the unit price has responded only modestly.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotify shares are drawing attention after its latest quarterly report, with traders focusing on subscriber growth, stronger gross margins and an upbeat profit outlook despite revenue and EPS misses. The sharp gain has surprised some investors, while skeptics point to rising expenses and the earnings shortfall.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTXs breakout to a fresh 52-week high has traders positioning around the Q3 earnings report and continued BRIUMVI growth, with the subcutaneous formulation also drawing attention. Buyout and short-squeeze speculation is adding to bullish sentiment, though some traders attribute the move to earnings expectations rather than a potential deal.

3M Co. is a technology company, which engages in manufacturing industrial, safety, and consumer products. It operates through the following segments: Safety and Industrial, Transportation and Electronics, Consumer, and Corporate. The Safety and Industrial segment consists of personal safety, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules. The Transportation and Electronics segment includes electronics, automotive and aerospace, commercial solutions, advanced materials, and transportation safety. The Consumer segment covers consumer healthcare, home care, home improvement, and stationery and office products, such as consumer bandages, braces, supports, respirators, cleaning products, retail abrasives, picture hanging, and consumer air quality solutions. The Corporate segment refers to special items and other corporate expenses. The company was founded by Henry S. Bryan, Hermon W. Cable, John Dwan, William A. McGonagle, and J. Danley Budd in 1902 and is headquartered in St. Paul, MN.

3M Co.

3Ms quarterly earnings beat and higher full-year outlook, alongside an expanded Amazon data-center products partnership, have driven attention. Some traders view the developments as supportive, while bears argue the rally overstates a conditional, long-term deal and are positioning for a pullback.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Organon (OGN) Q3 Earnings and Revenues Top Estimates

Organon (OGN) delivered earnings and revenue surprises of +3.30% and +0.43%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Organon Announces Quarterly Dividend

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the companys Board of Directors declared a quarterly dividend of $0.02 for each issued and outstanding share of the company's common stock...

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its third quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission (SEC). The...

Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that Sebela Womens Health will present interim results from an ongoing Phase 3 study evaluating MIUDELLA, a hormone-free, copper intrauterine...

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.

Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock

Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Organon to Present New Real-World Analysis of VTAMA (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that a new real-world analysis of patients with atopic dermatitis (AD) treated with VTAMA (tapinarof) cream, 1% will be on display at the 2026 Fall...

Is Trending Stock Organon & Co. (OGN) a Buy Now?

Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA, a Hormone-Free Intrauterine Device

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced the US Food and Drug Administration (FDA) has accepted for review Sebela Womens Healths supplemental New Drug Application (sNDA) for MIUDELLA...

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Organon & Co.

Gilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Pharmaceutical giants are aggressively pursuing acquisitions to offset looming patent cliffs, as major blockbuster drugs face loss of exclusivity over the next several years.</li><li>Firms are trying to add new drugs to their portfolio with their deals, expanding into new or supplementing existing therapeutic areas.&nbsp;</li><li>Average deal size has climbed to $527.3 million in 2026, up from $365 million in 2025, CNBC reported.</li></ul>Global biopharma mergers and acquisitions have accelerated sharply in 2026, with deal value reportedly reaching $106 billion across 201 transactions through early June.If the current pace continues, the sector is projected to exceed $250 billion in total deal value for the full year—the strongest performance since the 2019 pre-pandemic peak, CNBC <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2026/06/04/biotech-ma-dealmaking-pharma-106-billion.html">reported</a>, citing PitchBook data.Pharmaceutical giants are aggressively pursuing acquisitions to offset looming patent expiries, as major blockbuster drugs face loss of exclusivity over the next several years. Firms are trying to add new drugs to their portfolio with their deals, expanding into new or supplementing existing therapeutic areas.“Pharma companies [are] really buying stuff like it’s going out of fashion,” Rajesh Kumar, head of life sciences and healthcare equity research at HSBC, told CNBC.Activity has shifted heavily toward strategic “bolt-on” acquisitions in the $1 billion to $5 billion range rather than large leveraged buyouts or mega-mergers, Nanna Lüneborg, general partner at life sciences venture capital firm Forbion, told CNBC. She doesn’t believe pharma is panic buying, but noted that many companies are prioritizing products that are close to commercialization while also investing in earlier-stage assets to gain access to innovative new technologies.Average deal size has climbed to $527.3 million so far in 2026, up from $365 million in 2025, CNBC reported.&nbsp;<h2 class="st-heading-2">Five Biggest Mergers And Acquisitions In US Biopharma Space In 2026</h2>Here are the five largest announced year-to-date:<ul><li>Sun Pharmaceutical Industries acquires Organon: India’s Sun Pharma <a href="https://stocktwits.com/news-articles/markets/equity/ogn-stock-jumps-after-sun-pharma-all-cash-buyout-offer/cZBNaqaRe2f">agreed</a> to buy New Jersey-based Organon in an all-cash deal at $14 per share for an $11.75 billion enterprise value. Organon’s portfolio of more than 70 medicines, including a strong biosimilars and women’s health franchise, gives Sun immediate scale in the U.S., China, and Brazil.</li><li>Gilead Sciences (<a href="https://stocktwits.com/symbol/GILD">GILD</a>) acquires Arcellx: The $7.8 billion deal, <a href="https://stocktwits.com/news-articles/markets/equity/why-did-aclx-stock-surge-in-pre-market-gilead-acquisition/cZRtFxoR4yT">announced</a> in the first quarter and completed on April 28, bolsters Gilead’s oncology and autoimmune pipeline with Arcellx’s next-generation CAR-T cell therapy for multiple myeloma.</li><li>Merck &amp; Co. (<a href="https://stocktwits.com/symbol/MRK">MRK</a>) acquires Terns Pharmaceuticals: Merck purchased the California-based biopharma for $6.7 billion in a deal <a href="https://stocktwits.com/news-articles/markets/equity/merck-to-acquire-terns-signaling-fresh-push-in-competitive-cancer-drug-race/cZ3YnhpRISB">announced</a> in late March. The acquisition centers on Terns' oral drug candidate TERN-701 for chronic myeloid leukemia.</li><li>Eli Lilly (<a href="https://stocktwits.com/symbol/LLY">LLY</a>) acquires Centessa Pharmaceuticals: The $7.8 billion total consideration <a href="https://stocktwits.com/news-articles/markets/equity/cnta-stock-surges-pre-market-what-s-the-eli-lilly-connection/cZEPMWsRIV7">deal</a>, announced in March, targeted Centessa’s pipeline of experimental therapies for the treatment of excessive daytime sleepiness and related neurological conditions.&nbsp;</li><li>Biogen (<a href="https://stocktwits.com/symbol/BIIB">BIIB</a>) acquires Apellis Pharmaceuticals: Biogen gained the Massachusetts-based company’s approved therapies Syfovre and Empaveli, plus additional immunology assets, in a $5.6 billion <a href="https://stocktwits.com/news-articles/markets/equity/apls-stock-soars-after-biogen-acquire-5-6b-deal/cZEPMW3RIVe">deal</a> announced on March 31.</li></ul>The State Street SPDR S&amp;P Biotech ETF (<a href="https://stocktwits.com/symbol/XBI">XBI</a>), which tracks the S&amp;P Biotechnology Select Industry Index, has risen 9% year-to-date, trading near $130.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/gm-stock-climbs-as-former-cruise-team-reportedly-returns-to-build-hands-free-consumer-vehicles/cZ0ZZ0PRez5">GM Stock Climbs As Former Cruise Team Reportedly Returns To Build Hands-Free Consumer Vehicles</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A photo illustration showing a mix of various tablets and pharmaceutical products, primarily manufactured by U.S. pharmaceutical companies, photographed in Edmonton, Alberta, Canada, on April 10, 2025 (Photo by Artur Widak/NurPhoto via Getty Images)

Biopharma M&A has surged to $106 billion across 201 deals through early June 2026, putting the sector on track for its strongest full-year total since the 2019 pre-pandemic peak, CNBC reported.

Arcellx Inc

Apellis Pharmaceuticals Inc

Biogen Inc

Centessa Pharmaceuticals PLC - ADR

Gilead Sciences, Inc.

Lilly(Eli) & Co

Merck & Co Inc

Terns Pharmaceuticals Inc

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

OGN Organon & Co.

Fundamentals

Latest OGN News